Objectives: This study aimed to evaluate the feasibility, local efficacy and long-term outcomes of microwave (MW) ablation for the treatment of hepatocellular carcinoma (HCC) that met up-to-seven criteria.
Methods: Between January 2007 and January 2012, 142 HCC patients with 294 nodules, which conformed to up-to-seven criteria, were enrolled into this retrospective study. All patients were followed up for more than 3 years after receiving MW ablation. Technical success, complications, local tumour progression (LTP) and distant recurrence (DR) were monitored. Recurrence-free survival (RFS), overall survival (OS) and prognostic factors were analysed.
Results: Primary technical efficacy was achieved in 95.2% (280/294) of the carcinomatous nodules, and major complications occurred in four (2.8%) patients. Among the 294 tumours, LTP was observed in 44 (15.0%) tumours. Among the 142 patients, DR was observed in 97 (68.3%) patients. The estimated OS rates after MW ablation at 1, 3 and 5 years were 97.2%, 75.4% and 50.6%, respectively; and the corresponding RFS rates were 76.1%, 33.1% and 19.5%, respectively.
Conclusions: MW ablation is a safe and effective treatment with a high rate of primary technical efficacy for patients with HCC that met up-to-seven criteria.
Key Points: • The first study expanding MW ablation to HCC category beyond Milan criteria. • The first report that used up-to-seven criteria as indications for MW ablation. • HCC of up-to-seven criteria viewed as a subgroup of BCLC stage B. • MW ablation is safe and effective for treating HCC within up-to-seven criteria. • MW ablation is preferable in treating unresectable HCC within up-to-seven criteria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-017-4740-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study.
Invest New Drugs
January 2025
Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Purpose: The combination therapy of lenvatinib and immunotherapy as first-line treatment remains controversial in unresectable hepatocellular carcinoma (uHCC). This research aimed to compare the efficacy and safety of lenvatinib monotherapy (L) and combination therapy of lenvatinib and immune checkpoint inhibitor (LI) in lenvatinib-insensitive patients with uHCC.
Methods: Two hundred fifty-five uHCC patients were enrolled in this study.
How a Dysphonia App Can Promote the Motivation of Speech Therapists and Patients in the Long Term-A Qualitative Study in the LAOLA Project.
J Voice
December 2024
Carl von Ossietzky University Oldenburg, University Clinic for Visceral Surgery, Ammerländer Heerstraße 114-118, 26129 Oldenburg, Germany.
Objective: The care of patients with dysphonia will change due to the growing shortage of specialists, demographic change, and digitalization. To counteract the associated problems in patient care, the LAOLA app demonstrator is to be developed. In the future, patients will receive exercise videos for their training from their treating speech and language pathologist (SLP) via LAOLA.
View Article and Find Full Text PDFTransarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.
Ann Med
December 2024
Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Article Synopsis
- The study examines the effectiveness of combining transarterial chemoembolization (TACE) with molecular-targeted agents and immune checkpoint inhibitors (TACE-MTAs-ICIs) compared to TACE alone in patients with unresectable hepatocellular carcinoma (uHCC) that exceeds specific criteria.
- A total of 130 patients were involved, with results showing that those treated with TACE-MTAs-ICIs had significantly longer overall survival (27.2 months) and progression-free survival (15.4 months) compared to those receiving only TACE (15.9 months and 4.8 months, respectively).
- The TACE-MTAs-ICIs group also demonstrated a higher objective response rate
Prognostic Value of Myosteatosis and Albumin-Bilirubin Grade for Survival in Hepatocellular Carcinoma Post Chemoembolization.
Cancers (Basel)
October 2024
Department of Radiology, Faculty of Medicine, Prince of Songkla University, Hat Yai 90110, Songkhla, Thailand.
Article Synopsis
- This study investigates how preoperative myosteatosis and the albumin-bilirubin (ALBI) grade can predict outcomes for hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).
- The research involves analyzing 446 HCC patients, discovering that preoperative myosteatosis and higher ALBI grades are significant indicators of patient prognosis.
- A new prognostic score called Myo-ALBI was created, showing better predictive ability than existing models, which could help doctors make more informed treatment decisions for HCC patients.
Frontline evaluation: Atezolizumab-bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up-to-seven criteria.
Cancer Med
September 2024
Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
Introduction: This study aimed to evaluate the efficacy and safety of atezolizumab combined with bevacizumab (Atez/Bev) compared to lenvatinib (LEN) as first-line systemic therapy for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) exceeding the up-to-seven criteria threshold, who are typically unsuitable for transarterial chemoembolization (TACE).
Methods: A retrospective analysis was conducted on 49 consecutive patients with HCC treated at Tokyo Metropolitan Komagome Hospital between May 2018 and October 2023. The patients were divided into two groups: the Atez/Bev group (21 patients) and the LEN group (28 patients).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!